


1 / 14



Scheme 1. Synthesis of the GM-fluorescent ligands. (a) 6-(Boc-amino)-1-hexanol, TEA, DMF, 60 °C, 24 h; (b) TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:4), 45 min, rt; (c) GM, TEA, DMF, rt, 24 h; (d) GM, DIEA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 24 h.

Fig. 1




Fig. 2

2 / 14

Fig. 3





Fig. 4

3 / 14

Fig. 5








Fig. 6



5 / 14




Fig. 8

Fig. 9A





Fig. 9B



6 / 14




Fig. 10 A




Fig. 10 B

	Brain	K562	SKBr3
Sigmoidal dose-response			
Best-fit values			
BOTTOM	137.2	137.2	131.8
TOP	540.9	275.8	306.4
LOGEC50	1.233	-0.1382	0.1423
EC50	17.11	0.7274	1.388




Fig. 11

u  
axu protein 7  
Gm-BODIPY?

7 / 14




Fig. 12A




Fig. 12B

Fig. 13A




Fig. 13B




Fig. 13C

8 / 14




Fig. 14

Fig. 15A





Fig. 15B





9 / 14




Fig. 16A




Fig. 16B






Fig. 17

Fig. 18A




10 / 14


**Fig. 18B**



**Fig. 19**



**Fig. 20**



11 / 14




Fig. 21

12 / 14




Fig. 22A




Fig. 22B




Fig. 22C

13 / 14


**Tg3**  
**MDA-MB-468**

Fig. 23

14/14




Fig. 24